Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis

Guselkumab is an IL-23 inhibitor approved for moderate-to-severe plaque psoriasis that has demonstrated safety and efficacy in phase III clinical trials . However, there is scarce data regarding its drug survival in clinical practice.

Bibliographic Details

Published in:	British journal of dermatology (1951) 2021-09, Vol.185 (3), p.660-662
Main Authors:	Iznardo, H., Vilarrasa, E., López‐Ferrer, A., Puig, L.
Format:	Article
Language:	English
Subjects:	Monoclonal antibodies Psoriasis
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!